Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Over six is bullish. It will get there.
The shorts vs. Northwest Biotherapeutics from The Washington Post -- excerpt from the article.
http://wpo.st/ufrm0
"In late July, CREW’s executive director, Melanie Sloan, asked the Securities and Exchange Commission to investigate market manipulation of Northwest Bio’s stock. (Sloan told me her organization has never been contacted by the company and has no connection to its executives, investors or directors.)
In her letter, Sloan called particular attention to Adam Feuerstein, a biotech reporter whose relentlessly negative blog posts for thestreet.com this year have not only been filled with exaggeration, mischaracterization and half-truths, but curiously have also coincided with the spikes in short trading."
My comment: The propagandist understands how to influence others by using a modicum of truth.
I'm getting ready to buy more.
Expect KKD'S SA publication of Dr. MacFarlane 's collection of comments from participants and care givers. KKD mentioned yesterday that he obtained these from Dr. Michael M & planned to publish another SA article today.
Tomorrow KKD will post verbatim quotes Dr. MacFarlane has collected from trial participants and care givers. KKD said this in response to one of the people making comments about KKD'S article today.
I have bought more today.
Thanks for this. Yesterday, I said I was having difficulty grasping how the placebo effect could apply to these trials as Adam F alleged. Dr. MacFarlane addresses this.
Dr. MacFarlane in the interview says:
5. Of all the battery of tests which do you think most powerful for AD, and how did Anavex 2-73 perform in that test?
The One-back test (which measures working memory, a key domain of impairment in AD) within the Cogstate battery is the most difficult test, yet showed the greatest improvement. This outcome is unlikely to have been an artefact of any placebo effect...when placebo effects occur they are typically larger for the easier tests. In addition, whilst placebo effects are common with CNS sedative drugs, they are less likely to be present in tests of drugs used to enhance cognition...individuals cannot anticipate, or 'imagine' what a better score would consist of, and are unable to produce improved results through mere 'wishful thinking.'
Excellent, indeed. Everyone should read this. Thank you, JB, and thank you, Thes, for pointing this out.
Thank you.
I am having difficulty conceiving how the placebo effect may apply to an AD clinical trial as Adam F claimed this morning. For example, how could it account for improvements in the EEG/ERP (P300) signal? The P300 (P3) as I understand is a wave event component elicited in the process of decision making. P300 may be recorded by electroencephalography (EEG) -- measured by electrodes. It is an objective measure of brain waves.
Also, Alzheimer's robs AD patients of short term memory. How can the placebo effect make a difference in short term memory when AD patients have difficulty in remembering recent prescriptions, what they should be taking, and why?
Adam F would say that the mice knew they were administered Anavex 2-73, and that meaningless animal study obviously showed the results it did due to the placebo effect.
What can I say other than so very sorry.
This is epic! "Such an outcome in a trial such as this is unprecedented in my experience, and the current results suggest that ANAVEX 2-73 could potentially make a significant difference in patients’ lives,” said Associate Professor Stephen MacFarlane..."
Adam F, Martin S, and others like them do not care about making significant differences in patients' lives. They will attack and try to destroy the company for their personal profit. However, I sincerely hope that good prevails over evil. We all know someone that has a serious CNS disease, and need this to make a difference in their lives.
I am watching CNBC, Anavex early trades appears often on the tape with the share noticeably price increasing as the morning progresses. A lot of good volume to the upside. Adam F is the false!
Thanks.
What is her stepfather's name? I will see what I can find out.
Amateur: You may find this slide here: https://pbs.twimg.com/media/CTMsjZYWcAAZ6J5.jpg:large
Anavex trials for dummies (like me): The purposes of the AVXL current clinical trials does not include proving efficacy although the current trials indicate efficacy. The primary purpose of the study is to study safety and dose tolerance in the subjects; however, as secondary endpoints, the study has measured a battery of cognitive function metrics such as MMSE, ADCS-ADL, and EEG/ERP for exploratory purposes; and bioavailability of the oral capsule formulation.
These positive benefits have been demonstrated so far:
1. Safety is shown.
2. EEG/ERP (P300) signal improved. The P300 (P3) wave is an event related potential (ERP) component elicited in the process of decision making. P300 may be recorded by electroencephalography (EEG) -- measured by electrodes. It is an objective measure of brain waves. (With a great deal of escort Scott in Post# 32247 has concluded it appears November results show, on average, all 36 patients were closer to the healthy control than the 12 patients were in July.)
3. Cognate (underlying skills) test improved across the test batteries.
4. MMSE -- Mini Mental State Examination -- scores improved.
5. Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL), although maybe not great, did show overall improvement.
4. PK (pharmacokinetic) and receptor pharmacology profile...are not issues despite what Martin Shkreli, a short, has tweeted.
People attending the November 7, 2015 Alzheimer's conference Barcelona believe the trials show promise and will continue to the next phase or phases. A number of scientific articles support the Anavex theory that the receptors target by Anavex therapy are key to treating AD and other CNS diseases. Besides the ongoing human clinical trial by Anavex, animal studies show promising support.
The bottom line is that efficacy is yet to be proven by further phases of this clinical study, but results so far are very encouraging. The FDA and experts in the field admit that the drugs approved to treat AD are not working except possibly Donepezil (Aricept) that alone has some limited benefit and possibly when combined with Anavex 2-73 may have much more significant benefit.
Efficacy is yet to be clinically proven. On the other hand, no person can say with any credibility (any credible scientific evidence) that Anavex and its therapy will fail.
We will know by tomorrow morning, November 9, 2015, when Anavex posts late breaking news about the clinical trials. The latter was the subject discussed at the Barcelona conference yesterday. Some slides tweeted from that conference are interesting. One is entitled: "Anavex 2-73 Reverses Cognitive Deficits Measured by Standard ERP Methods at week 5" . You may find this slide here: https://pbs.twimg.com/media/CTMsjZYWcAAZ6J5.jpg:large
The Anavex science is credible, and it has been supported in great depth. On the other hand, Anavex has been attacked by shorts hoping to make a quick profit by publishing inflammatory and deceitful statements. The corrupt Martin Shkreli is a prime example of a professional short that dishonesty influences people for his personal benefit. He understands he can provide a couple of pharmaceutical terms in a cryptic chirping note ( a "tweet") and then throw out a totally unsubstantiated selfserving unqualified biased opinion that "Anavex (and I suppose its imminently qualified scientific board) is worthless" to sway the uninformed.
Greenspam: . Thank you for this.
Correct. Clearly, we have not seen all the data. I have been through a lot in my life, war in the 1960s, agent orange exposure, cancer, death of friends and close ones, bad times and also good times, ups and downs (including financial ups and downs), but I have persistently stuck with what I believe in although it has not been easy. Big things in life are never easy. If it were easy to develop drugs to significantly treat or cure dreaded diseases like AD, Parkinson's, cancer, and epilepsy every drug company would have already done it, and we would not be having these discussions on this board.
I will stay long AVXL. There will be peaks and valleys. The science still looks promising. My success and survival in life has been from never giving up as long as I believe in what I am doing.
As to the likes of Martin Shkreli, "..though I walk through the valley of the shadow of death, I will fear no evil."
It is amazing. It is time for them to just forget it and wait for tomorrow.
Minotaur is right.
CBD: I appreciated your post of words of wisdom. I appreciate most of the members of this board. I am long and have no regrets "Life is too short to have regrets. So, appreciate the people who treat you right. Forget about the ones who don't. Believe everything happens for a reason. If you get a chance, take it & if it changes your life, let it. Nobody said life would be easy, they just promised it would most likely be worth it." Quote from the book Canada by Richard Ford.
The abstract is very effective: "A majority of all patients improved their respective MMSE score." We do not know how many patients improved MMSE scores or how much those patients improved. However, drugs that have only benefited about 30 some odd % of the patient population have been approved by the FDA. EEG/ERP (P300) signal improved, and Cognate test improved across the test batteries. All of this is positive.
I do not think the abstract was sloppiedly worded. I do think it is purposely sketchy in its wording. It is a mystery that is certainly drawing a great deal of attention. It keeps everyone guessing until the conference on Saturday. Intended or not, the impact and exposure will be much greater because of all of this. This is all a mystery until Saturday. It holds all of us and many more in suspense. It will get greater coverage in all of the media, and the news will be positive.
I read the abstract to say that "the analysis of the data shows an average improvement of the MMSE score" and that complete details of that analysis will be available at the time of the conference -- meaning that the average improvement of the 32 subjects is____% at that time. In other words, the presenters will give the average percentage of improvement of the 32 subjects taking part in the trial. Traders do not know what that percentage of improvement is. We will know from the presentation.
Involvement of the sigma-1 receptor in neurodegeneration an neuroprotection! Anavex 2-73 has indicated that its therapy positively stimulates the appropriate receptors, such as sigma-1, to treat CNS disorders before, and who is to say it with any authority that this will not be confirmed. The applications to combat neurodegeneration and for neuroprotection are enormous.
I said in my last post that there was not enough time to enlighten newcomers to this board, but this synopsis proves that I was wrong. This is an excellent post supported by the scientific article Orveko revealed to this board earlier today. Orveko: Thank you.
AVXL is very dangerous for shorting at this juncture. Long time posters on his board understand this. We have spent many months elaborating about why Anavex drug therapy should succeed based on the science. Not enough time exists to enlighten or inform new members, whether long or short. We will learn more from Barcelona in the next few days. It will be good news for the benefit of society and the advancement of the human race, although it may be considered bad news for a few. Let it be! Let it be!
Thanks for doing that.
Motley Fool article today. Apparently, the author does not know about the presentation in Barcelona. Mentions AVXL far to risky until phase 2 data is out, and that is not likely until next year. Oh well, it's the Fool. The article was probably hurriedly put together just to attract new customers to sign up. It's here:
http://www.fool.com/investing/general/2015/11/02/why-anavex-life-sciences-shares-are-soaring-15-tod.aspx
I am staying long. Break through therapy designation is possible for early FDA approval!
Break through therapy designation is for real. Stay long! See also this link:
www.focr.org/breakthrough-therapies
This is a MUST READ! I think we need to confirm it though.
Thanks. Pumper Stopper, the despicable coward - anonymous author, deserves a place in jail.
Can it be shown that SA knew that Pumper Stopper was manipulating the market by spreading false information?
I am not sure, but I will try to find out. I just noticed the article, because "Pumper Stopper" authored a 58 page article published by Seeking Alpha attacking APDN Thursday. The interesting thing is that APDN begin dropping in value earlier in the day before the Seeking Alpha article was published. How about that? I noticed it dropping a fair amount that morning. In the afternoon, I noticed the stock was down more that 50% after the article was published. I read the 58 page Pumper Stopper article, which used some tactics like those employed against AVXL. It used familiar strategy that I have tried to articulate in posts that I published on this board about how short seller cartels work. I purchased some shares of APDN that afternoon at a low price. It rose a bit by the close, and it closed higher yesterday.
Yes, we have experienced various short attacks, and those longs that have not panicked have seen their shares rise overall despite a few brief dips caused my the mauraders in their attempts to make a small amount of profit before moving on to the next target. AVXL IS NOT THE FIRST TO BE TARGETED AND WILL NOT BE THE LAST. For example, I got this elsewhere:
NEW YORK, June 15, 2015 /PRNewswire/ -- root9B Technologies, Inc. (OTCMKTS: RTNB), a leading cybersecurity, regulatory and risk mitigation company, responded today to false statements and allegations made by the financial blogger known as "The Pump Stopper."
The Pump Stopper is an anonymous author who issued a report about root9B Technologies that is rife with inaccuracies and factual mistakes, including the suggestion that insiders are selling stock. The company believes the sole purpose of this report is to benefit the anonymous author who, in a disclaimer, states he has a short position in shares of root9B Technologies.
root9B Technologies has taken action based on these allegations. This afternoon, the company has asked Harvey Pitt, former Chairman of the Securities & Exchange Commission and an independent director of root9B Technologies, to review the issue and recommend appropriate responses to the allegations.
root9B Technologies issued the following statement in response to the anonymous author's allegations:
"root9B Technologies is appalled and incensed by the baseless anonymous blog attacks posted today by a short seller that seek to cast aspersions on both the Company's business operations as well as the integrity of its senior management team and Board. Our Company is at the forefront of important cybersecurity developments and solutions, among other innovative business solutions, and has been recognized internationally for its unique ability in detecting and thwarting, in advance, a cyber attack against the Nation's top financial institutions. The personal attacks on our personnel are wholly unwarranted, and appear designed to advance the anonymous blogger's short strategy, rather than provide a serious analysis of our Company's operations and capacity for future success.
"The Board today asked one of its independent directors, former SEC Chairman Harvey L. Pitt (who has never purchased or sold a single share of Company stock, despite allegations to the contrary in the blog post), to review the allegations contained in the blog posting and to recommend appropriate responses for the Company to these allegations. It is expected that Mr. Pitt will report his findings to the Board, and to appropriate regulatory authorities at the completion of his review."
We also have a resident expert on Cannabidiol (CBD) thanks to Cbdpotential. This is an amazing board. Thank you Cbdpotential for piecing this together. This is very interesting. Think about that some more. Consider that some families have been moving to Colorado where they will not be jailed for treating their children for seizures with cannabis or some derivative therefrom. Is there a link?
Precisely! That is exactly what this despicable little cartel deserves.